The simple version

A milestone payment is money one company promises to pay another only if something specific happens later, such as a product passing a testing stage, getting cleared for sale, or reaching a sales level. An upfront payment is paid when the deal is signed. Deal headlines usually add the two together and call the total what the deal is worth up to.

Regeneron and Sanofi showed the gap when they expanded their antibody partnership. The deal was reported as worth up to $8 billion. Of that, $1 billion is the upfront payment, and the other $7 billion depends on events that have not happened yet, for products that are mostly not yet tested in people.

The numbers

• Regeneron will receive an upfront payment of $1 billion from Sanofi (Regeneron and Sanofi, joint press release, October 1, 2026)
• Regeneron can also receive development, regulatory, and commercial milestone payments of up to an additional $7 billion (Regeneron and Sanofi, October 1, 2026)
• The companies will share development and commercialization costs for the new programs and split future profits from them 50:50 worldwide (Regeneron and Sanofi, October 1, 2026)
• The deal adds four long-acting antibodies invented by Regeneron. One, REGN20423, is in a Phase 1 trial for atopic dermatitis, and the other three are expected to enter clinical studies in 2027 (Regeneron and Sanofi, October 1, 2026)
• The existing profit-sharing agreement for Dupixent does not change, and the companies settled their prior collaboration-related litigation (Regeneron and Sanofi, October 1, 2026)

How a deal headline gets to up to

Development takes years and the outcome is uncertain, so the buyer splits the price. A smaller amount is paid now for the rights. Larger amounts are promised for each later step, from testing progress to sales targets.

The up-to figure is the total if every milestone is reached. It is a ceiling, not an expected value. The announcement does not say how the $7 billion is divided among milestones or when each could be paid, so the headline cannot tell a reader how much is likely or how soon.

The headline also counts money flowing one way. Under these terms, Regeneron pays half of the development and commercialization costs for the new programs. A reader comparing the $8 billion to anything should keep both sides in view.

The actual math on up to $8 billion

This lens uses only the figures in the release. The split is the companies'; the shares of the total are our arithmetic.

• Upfront: $1 billion, paid under the agreement.
• Contingent: up to $7 billion, paid only if milestones are met.
• $1 billion divided by $8 billion is 12.5% of the headline.
• $7 billion divided by $8 billion is 87.5% of the headline.

Seven of every eight headline dollars are tied to results that have not happened, and the announcement does not say which results or when. Meanwhile, the cost-sharing terms mean money also flows the other way while the work goes on. The upfront payment is the only part of the headline that is settled.

What this means

When a licensing deal is described as worth up to a figure, three things in the announcement do most of the explaining. The upfront amount, the kinds of milestones (development, regulatory, commercial), and who pays the costs in between. Releases like this one state the upfront amount next to the total.

Milestone money is paid for progress, so it arrives in steps if it arrives at all. Commercial milestones can only come after a product is approved and selling, so they sit at the end of the sequence. Reading the deal that way turns one large number into a sequence of conditions.

What this is NOT

This article explains how milestone and upfront payments work, using the October 1, 2026 Regeneron and Sanofi announcement as the example. It is not a recommendation to buy, sell, or hold Regeneron, Sanofi, or any security, and it takes no view on either company's valuation or on whether the deal is good for either side. It does not predict whether any milestone will be reached, whether any of the antibodies will succeed in trials or win approval, or how much of the $7 billion will ever be paid. The 12.5% and 87.5% figures are our arithmetic on the release's numbers, not company-published percentages. It does not describe the safety or medical use of any drug and is not medical information. This is not a political endorsement or criticism of anyone.

Sources

• Regeneron Pharmaceuticals and Sanofi, Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies, press release, October 1, 2026: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-expand-global-alliance-multiple-next